Compare Ginkgo Bioworks Holdings Inc (DNA) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Annaly Capital Management, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Annaly Capital Management, Inc. trades at $23.11 (market cap $17.44B). The key difference: Annaly Capital Management, Inc. is far larger — about 34.5× Ginkgo Bioworks Holdings Inc's market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NLY | |
|---|---|---|
Market Cap | $505.73M | $17.44B |
Sector | Health | Financials |
52-Week High | $16.14 | $24.40 |
52-Week Low | $5.48 | $20.21 |
Enterprise Value | $607.68M | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
NLY trades at $23.23, up 1.4% with strong technical momentum as moving averages signal bullish sentiment. The stock demonstrates robust fundamentals with a low P/E of 5.59 and impressive 92.77% net income margin, supported by three consecutive quarterly earnings beats. Recent analyst upgrades and institutional buying reflect growing confidence in the mortgage REIT's housing finance strategy and dividend sustainability.
Outlook remains positive with consensus price target of $24.50 offering 5.5% upside potential. Key opportunities include the 13%+ dividend yield and diversified housing finance platform, while risks center on interest rate volatility and the company's high leverage ratio of 23.55. Earnings growth momentum and institutional support provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
